Background: Mycobacterium bovis bacillus Calmette Guérin (BCG) vaccine, which has been inoculated to more than one billion people world-wide, has significant effect in preventing tuberculous meningitis and miliary tuberculosis (TB) in neonate and early childhood. However, BCG fails to adequately protect against pulmonary TB and reactivation of latent infections in adults. To overcome this problem, adequate booster is urgently desired in adult who received prior BCG vaccination, and appropriate animal models that substitute human cases would be highly valuable for further experimentation.
Introduction
The protective efficacy of BCG vaccine is variable from 0 to 80% in many field trials and uncertain to pulmonary TB in adult [1] . The several reports showed that the effectiveness of prime BCG vaccination would last for around 15-24 years [2, 3] . To solve the problem of current BCG vaccine the prime-boost vaccine strategy against TB was investigated strategy [4, 5] . In most of the trials in mice, however, intervals between priming and boosting were only 4-8 weeks, which correspond to 2 years in human. Furthermore, the immune response against MTB reaches its peak within several weeks after prime vaccination. Thereby, to evaluate the booster in adult human, it is necessary to investigate the boosting effect in aged animals primed with BCG. The transition of immune system with increasing age has been reported by analyzing the population of T cell subsets [6] [7] [8] . However, the reports investigating the duration of efficacy of BCG vaccination and the shift of memory type T cell subsets with increasing age are very few. In this study we investigated the efficacy of prime BCG vaccine with aging by analyzing memory T cell subset, immune responses to TB antigens, and also protection activity against MTB infection in animal model. We also evaluated the effect of boosting with Oligo-B to the protective immunity against TB in BCG-primed aged mice.
Materials and methods

Bacterial strains and cultures 2. Mice and immunization
The methods were described in our previous study [9] . The protocol of animal study was approved by the Ethics Committee of Nagoya City University.
Whole blood assay
The whole blood was stimulated with purified protein derivative (PPD) (Japan BCG co., Tokyo, Japan) for 18 h. Then, the supernatant were collected and the amount of interferon gamma (IFN-γ) was measured by enzyme-linked immunosorbent assay (ELISA), using a BD OptEIA TM ELISA set (BD Bioscience, San Jose, CA).
Flow cytometric analysis of surface markers
Splenocytes from young and middle-aged mice were washed by FACS buffer and stained with PE rat anti-mouse CD8a (BD Bioscience, San Jose, CA) and FITC rat anti-mouse CD4 (BD Bioscience, San Jose, CA), then analyzed by FACS. MACS TM (Miltenyi Biotec, Tokyo, Japan) -purified splenocytes CD4 + and CD8 + T cells were stained with PE rat anti-mouse CD44 and FITC rat anti-mouse CD62L (BD Bioscience, San Jose, CA), then cells were analyzed by FACS.
Protection assay against infection with MTB
The precise method was described in our previous study [9] . 6. Splenocytes stimulation Splenocytes prepared from BCG-immunized with or without Oligo-B (GGGGGGGGGGGG AACGTTGGGGGGGGGGGG) (Nihon Gene Research Laboraroties, Inc., Miyagi, Japan) or Oligo-B negative (GGGGGGGGGGGG ACCGGTGGGGGGGGGGGG) (Nihon Gene Research Laboraroties, Inc., Miyagi, Japan) mice were incubated in a 24-well plate, at a concentration of 5 × 10 5 cells per well. Cells were stimulated with 10 μg/ml of PPD for 48 h. The productions of IFN-γ in the supernatants of splenocytes were determined by the ELISA set.
Statistical analysis
The methods were described in our previous study [9] .
Results
1.
The reduction of interferon-γ production from antigen-stimulated T cells of mice immunized with Mycobacterium bovis bacillus Calmette Guérin (BCG) with aging The difference of the PPD-induced IFN-γ production between unvaccinated and vaccinated mice with BCG at 4-week old was remarkable until 49-week old mice (Figure 1a-1g) , however, it was not significant in 57-week and 83-week old mice (Figure 1h and 1i). The PPD-induced IFN-γ production in unvaccinated mice was comparable to that of BCG vaccinated super aged mice (83-week old) ( Figure 1i ). The immune response to ovalbumin (OVA), non-specific antigen, increased in both unvaccinated and BCG vaccinated 83-week old mice ( Figure 2b ). These results suggest that the immune responses specific to tuberculosis antigen decreased, and conversely nonspecific immune responses increased with aging and were supported previous studies about immune senescence with aging [6] [7] [8] [10] . The population of both T EM and T CM in CD8 + slightly decreased in BCG-vaccinated 90-week old mice (Table 1 , BCG vaccination; 87.51 ± 6.94 vs un-vaccination; 95.90 ± 0.82). These data suggest that the immunization with BCG is not sufficient to induce long term memory type T cells.
Boosting with Oligo-B
Several researches reported that Th1 type responses, such as production of IFN-γ against PPD, were reduced with aging and the immunization with BCG was not sufficient to induce long term memory T cells [10, 11] . We have previously reported that CpG oligomer (Oligo-B) activate Th1 response [12] and enhanced the delayed type hypersensitivity against PPD [13] . Therefore, we investigated the boosting effect of Oligo-B on the reactivation of immune senescence mice. Three times boosting with Oligo-B, but not Oligo-B negative, remarkably augmented the production of IFN-γ from splenocytes stimulated with PPD in the BCG vaccinated mice (Figure 3) , and CD4 + memory type T cells were strongly induced by the boosting (Table 1, CD4 + CD44 hi CD62L high in 90-week old mice: after boosting; 7.76±3.26 vs before boosting; 2.85 ± 0.67). These results strongly suggest that the boosting with Oligo-B can effectively reactivate the memory T cells developed by primary vaccination. 4. The effect of boosting with Oligo-B on the protectiveness against MTB in aged mice primarily vaccinated with BCG The bacterial numbers of MTB H 37 Rv challenged intravenously were reduced in the spleen and lung by BCG vaccination in 30-week old mice (Figure 4a and 4b) . However, at 89-week old, the reduction of challenged MTB number was not significant as compared to unvaccinated control mice (Figure 4c and 4d, open column). After three times boosting of Oligo-B on the 84-week old mice vaccinated with or without the prime BCG vaccination, these mice were challenged with MTB H 37 Rv intravenously at 90 weeks old. The bacterial numbers decreased in the lungs and spleens from the mice vaccinated prime BCG plus three times boosting with Oligo-B (Figure 4c and 4d, unvaccinated (open column) vs BCG plus OligoB (solid column)). These data indicate that Oligo-B rejuvenates the weakened protective immunity against MTB infection in BCG-primed aged mice. Figure 1 The change of IFN-γ production from whole blood cells stimulated with PPD in mice with increasing age. C57BL/6 mice were subcutaneously vaccinated with BCG (10 6 CFU) or PBS (unvaccinated). Whole-blood obtained from a) 13-week old, b) 18-week old, c) 24-week old, d) 28-week old, e) 31-week old, f) 40-week old, g) 49-week old, h) 57-week old, i) 83-week old was stimulated with purified protein derivative (PPD, solid column) or PBS (open column) and incubated for 24 h. The concentration of interferon-gamma (IFN-γ) from the culture supernatant was measured by ELISA. Results are shown as mean ± SD from groups of 16 animals. ** p < 0.01,* p < 0.05, N.S.: not significant.
Discussion
In this study, we first analyzed the age related changes of immune responses to MTB antigens, in super aged mice (up to 89-week old) vaccinated with BCG in 4-week old. The IFN-γ production from whole blood cells from C57BL/6 mice immunized with BCG at 4-week old increased up to 13-week old and sustained to 49-week old (Figure 1 ). These results are consistent with our previous Figure 2 The IFN-γ production from splenocytes stimulated with OVA in BCG vaccinated young and middle-aged mice. Splenocytes were prepared from BCG-vaccinated or non-vaccinated a)13-week old, b) 89-week old mice, and plated in a 24-well plate, at a concentration of 5 × 10 5 cells per well. Cells were stimulated with 100 μg/ml of ovalbumin (OVA, gray column), 10 μg/ml of PPD (solid column) or PBS (open column) and incubated for 48 h. Then, supernatants were collected and the concentration of IFN-γ was measured by ELISA. Results are shown by mean ± SD from groups of 3 mice. ** p < 0.01, * p <0.05, N.S.: not significant. report [14] . We also found the accumulation of CD8 + T cells (data not shown) and increased IFN-γ production from splenocytes stimulated with OVA with increasing age (Figure 2) . Kim et al. reported that the non-specific type immune responses increased with increasing age [15] . The productions of tumor necrosis factor-α and IL-6 both in healthy individuals and patients suffering from age related diseases increased with aging [16] . These studies indicate that the age related immunological changes and immune senescence in human are commonly observed in mice, and duration of initial BCG vaccine would be extinguished up to 57-week old.
Next, we investigated the reactivation of the protective immunity against MTB infection in the immune senescent mice by Oligo-B boosting (Figure 3 ). The CpG oligomer was used as adjuvant conjugated with BCG [17] or MTB antigens, such as Ag85B [18] , MPT-51 [19] , and MTB culture filtrate proteins [20] . The synthesized CpG oligomer, Oligo-B, induced antigen presentation through toll-like receptor 9 (TLR-9) signaling in plasmacytoid dendritic cells [21] and the production of Th17 cytokines [22] , which is known to play an important role in host defense against MTB infection [23] . Therefore, these studies indicated that CpG oligomer is a good inducer of IFN-γ and IL-17 and reactivates acquired immunity. In fact, the production of IFN-γ was reactivated by three times boosting of Oligo-B in the super aged mice (Figure 3) , therefore, Oligo-B could generate the number of the memory T cell by IFN-γ and IL-17.
Several studies reported that CD4 + memory T cells were induced by BCG vaccination [24, 25] . In our study the number of T CM , CD44
hi , CD62L hi , in CD4 + was highly induced by the boosting with Oligo-B in the immune senescent 81-90-old mice (Table 1, 2.85 ± 0.67 vs. 7.76 ± 3.26) and protection activity against MTB was rejuvenated ( Figure 4) . These results suggest that Oligo-B could induce T CM in CD4 + which improved protection activity against MTB infection.
In conclusion, this is the first report indicating that Oligo-B boosting can rejuvenates the number of T CM in CD4+ and reactivate the protection immunity against MTB infection in the immune senescent state mice formerly vaccinated with BCG. This report also provides basic information to explore the prime-booster strategy for preventing TB in adult. 
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